NasdaqCM - Nasdaq Real Time Price USD

Soligenix, Inc. (SNGX)

Compare

3.2000

-0.0700

(-2.14%)

At close: January 10 at 4:00:00 PM EST

3.2000

0.00

(0.00%)

After hours: 7:49:53 PM EST

Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trial

The randomised, placebo-controlled FLASH2 trial aims to enrol nearly 80 patients with early-stage cutaneous T-cell lymphoma.

Clinical Trials Arena 24 days ago

SNGX
-2.14%
Soligenix initiates confirmatory Phase 3 trial of HyBryte

Soligenix (SNGX) announced that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte in the treatment of cutaneous T-cell lymphoma, CTCL. The confirmatory Phase 3 study builds on the previous statistically significant Phase 3 study, as well as a recent successful comparative study and an ongoing investigator-initiated study, each further supporting the design of the FLASH2 clinical trial. Published first on TheFly – the ultimate source for real-time, market-movi

TipRanks 24 days ago

SNGX
-2.14%
SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway…

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 FLASH2 Trial of HyBryte in CTCL is Underway On December 16, 2024, Soligenix, Inc. (NASDAQ:SNGX) announced that patient enrollment has opened up for the confirmatory Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial of HyBryte™ in patients with cutaneous T cell lymphoma (CTCL). The

Zacks Small Cap Research 25 days ago

SNGX
-2.14%
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). The confirmatory Phase 3 study (Fluorescent Light Activated Synthetic Hypericin 2, FLASH2), builds on the

PR Newswire 25 days ago

SNGX
-2.14%
EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer

On Monday, Soligenix, Inc. (NASDAQ:SNGX) said it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL). The confirmatory Phase 3 study, FLASH2, builds on the previous statistically significant Phase 3 (FLASH) study, as well as a recent comparative study (HPN-CTCL-04) and an ongoing investigator-initiated study, each further supporting the design of the FLASH2 clinical trial. Also Read: Soligenix Kickstarts D

Benzinga 25 days ago

SNGX
-2.14%
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit Virtual Conference presentations are now available for on-demand viewing. Participants and those ...

ACCESSWIRE last month

IMUX

OESX

SPGC
HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that analysis of the post-treatment data from the open-label study (protocol HPN-CTCL-04) comparing HyBryte™ (synthetic hypericin) to Valchlor® (mechlorethamine) has demonstrated continued improvement in HyBryte™ treated patients and their individual lesions even after stop

PR Newswire last month

SNGX
-2.14%
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 /DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City, NJ. Now in its second year, the event is a ...

ACCESSWIRE last month

NNVC

UBI.AX

UBIO.AX
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a European Medical Advisory Board (MAB) to provide additional medical/clinical strategic guidance to the Company as it advances its confirmatory Phase 3 multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of HyBryte™ (synt

PR Newswire last month

SNGX
-2.14%
Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

PRINCETON, NJ / ACCESSWIRE / November 15, 2024 / Soligenix, Inc. (Nasdaq:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

ACCESSWIRE last month

SNGX
-2.14%
Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels

On Thursday, Soligenix Inc. (NASDAQ:SNGX) opened patient enrollment for its DUS-AUBD-01 Phase 2 study evaluating SGX945 (dusquetide) for Behçet's Disease, an inflammatory disorder of the blood vessels (vasculitis). The company looks forward to completing enrollment and announcing study results in the first half of 2025. The pilot clinical trial of SGX945 will be an open-label study that will enroll approximately 25 patients aged 18 years or older with mild to moderate Behçet's Disease and active

Benzinga last month

SNGX
-2.14%
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment for its Phase 2 study (protocol number DUS-AUBD-01) evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease.

PR Newswire last month

SNGX
-2.14%
SNGX: Phase 3 CTCL Trial to Initiate Before End of 2024

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 CTCL Trial to Initiate Before End of 2024 Soligenix, Inc. (NASDAQ:SNGX) is on track to initiate a confirmatory Phase 3 trial of HyBryte for the treatment of cutaneous T cell lymphoma (CTCL) before the end of 2024. The FLASH2 trial will be very similar in design to the Phase 3 FLASH trial, as shown in the

Zacks Small Cap Research last month

SNGX
-2.14%
Soligenix Third Quarter 2024 Earnings: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023)

Soligenix ( NASDAQ:SNGX ) Third Quarter 2024 Results Key Financial Results Net loss: US$1.72m (loss widened by 3.4...

Simply Wall St. last month

SNGX
-2.14%
Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended September 30, 2024.

PR Newswire 2 months ago

SNGX
-2.14%
Soligenix Announces Participation at the Spartan Capital Investor Conference

Premier Event to Showcase Growth Companies and Foster High-Level Investor EngagementNEW YORK, N.Y. - (NewMediaWire) - October 29, 2024 - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on deve...

NewMediaWire 2 months ago

SNGX
-2.14%
Soligenix, Inc. to Present at the 2024 ThinkEquity Conference

PRINCETON, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other indust

GlobeNewswire 2 months ago

SNGX
-2.14%
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Hong Kong Patent Office has granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin". The newly issued patent's claims are directed to a novel, highly purified form of synthetic hypericin manufactured through a unique proprietary process.

PR Newswire 2 months ago

SNGX
-2.14%
Soligenix Invited to Present at Upcoming Investor Conferences

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will be providing a corporate update at the upcoming investor conferences on the dates below.

PR Newswire 2 months ago

SNGX
-2.14%
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that two of its lead investigators are presenting findings from recent additional, supportive trials with HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). The presentations will occur at the European Organisation for Research and Treatmen

PR Newswire 3 months ago

SNGX
-2.14%

Performance Overview

Return	SNGX	S&P 500
YTD	+9.97%	-1.35%
1-Year	-77.01%	+22.51%
3-Year	-98.07%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Soligenix, Inc. (SNGX)

Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trial

Soligenix initiates confirmatory Phase 3 trial of HyBryte

SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway…

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

SNGX: Phase 3 CTCL Trial to Initiate Before End of 2024

Soligenix Third Quarter 2024 Earnings: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023)

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Soligenix Announces Participation at the Spartan Capital Investor Conference

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Soligenix Invited to Present at Upcoming Investor Conferences

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Performance Overview